3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
163
Endometrial Neoplasms
13
Ovarian Neoplasms
12
Fallopian Tube Neoplasms
5
Recurrence
4
Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Intraductal, Noninfiltrating
4
Triple Negative Breast Neoplasms
3
Breast Diseases
3
Breast Cancer Metastatic
3
Prostatic Neoplasms
2
Leiomyosarcoma
2
Carcinoma, Lobular
2
Advanced Breast Cancer
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Polycystic Ovary Syndrome
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Pain
1
Osteoporosis
1
Neoplastic Cells, Circulating
1
Neoadjuvant Operable Breast Cancer
1
Multiple Endocrine Neoplasia Type 1
1
Medullary cystic kidney disease 1
1
Lymphangioleiomyomatosis
1
Interventions
bicalutamide
4
pembrolizumab
1
nilutamide
1
exemestane
1
darolutamide
1
cabazitaxel
1
apalutamide
1
abemaciclib
1
Vorinostat
1
Triptorelin Pamoate
1
Tamoxifen
1
Letrozole
1
Histamine H2 Antagonists
1
Histamine Antagonists
1
Goserelin
1
Doxorubicin
1
Dasatinib
1
Cisplatin
1
CP protocol
1
Aromatase Inhibitors
1
Antiemetics
1
Anastrozole
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bulbo-Spinal Atrophy, X-Linked
×
Letrozole
×
Clear all
NCT02910050
2017-12-22
BETTER
Sun Yat-sen University
Phase 2
Unknown
58 enrolled